Project Grant R43AI192163
Award Date
4/22/25
Completion Date
3/31/26
Dollars Obligated
$299K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This $128,461 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program aims to develop an adaptive framework for rapidly synthesizing and reconfiguring bacterial viruses (phages) to counter antibiotic resistance. The key products and services to be delivered under this 2-year award include: 1) optimizing an E. coli cell-free...
This $714,053 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop an optimized "n-phage cocktail" for treating extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) infections. The key products and services to be delivered include: Developing a translational LC-MS/MS assay for quantifying the five individual phages in the cocktail (LUZ19, E215, PYO2,...
This $233,250 federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to determine how palmitoleic acid can potentiate the efficacy of the antibiotic vancomycin against Staphylococcus aureus and Enterococcus faecalis, including resistant and persister cell strains. The research will evaluate this therapeutic combination in a pre-clinical diabetic wound infection...
This $112,077 Project Grant award, granted by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of novel bacteriophage-based therapies to combat dual-species biofilms formed by the opportunistic pathogens Pseudomonas aeruginosa and Candida species. The research aims to create combination treatments that utilize antimicrobial peptides and engineered phages to target these mixed-species...
This $1,444,195 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to discover strategies to enhance the activity of topoisomerase inhibitors against antibiotic-resistant Escherichia coli and Pseudomonas aeruginosa pathogens. The key objectives are to: 1) identify metabolites that can modulate persistence and resistance development in these bacteria toward...
This $870,531 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund the development and validation of an innovative microfluidic capillary electrophoretic (CE) platform to study and characterize bacteriophages and their interactions with host bacteria. The platform will enable the separation, culturing, manipulation, imaging, and molecular-level analysis of individual phage...
This $273,644 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of synthetic RNA-based sensors, termed "encrypted RNA" (EncRNA), to enable high-throughput, quantitative screening for discovering new classes of broad-spectrum antiviral therapeutics. The goal is to create a versatile platform that democratizes broad-spectrum antiviral development...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel class of antimicrobial agents called Anti-infective Conjugated Electrolytes (ACEs) to combat antimicrobial resistance (AMR). The $299,995 award to Xiretsa Inc. will fund the assessment of ~40 ACE compounds synthesized in partnership with the NIH Center for Combating Antibiotic Resistant...
This $173,030 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will develop a novel assay for receptor-guided discovery of environmental bacteriophages (phages). The goal is to create a generalized method to preferentially isolate phages that require specific bacterial membrane proteins or structures for infection. This could be useful for understanding bacterial membrane dynamics...
This $764,423 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a transformative, rapid antimicrobial susceptibility testing (AST) system. The key objectives are to: 1) directly isolate and enrich bacteria from whole blood without expansion culture, 2) demonstrate compatibility of the exclusive liquid repellency (ELR) AST method with label-free imaging and...